SIH Partners’s Summit Therapeutics SMMT Stock Holding History

SIH Partners’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-46,492	Closed	-$897K	–	286
2025 Q1	$897K	Buy	+46,492	New	+$933K	0.03%	123

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

SIH Partners's SMMT Position: Q2 2025 in Review

SIH Partners sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 46,492 shares — an estimated $897K sold.

SIH Partners first reported a position in SMMT in Q1 2025 and held it in 1 quarter. The position peaked at $897K in Q1 2025. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

SIH Partners reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
SIH Partners sold 46,492 Summit Therapeutics shares in Q2 2025, an estimated $897K.
SIH Partners first reported a position in Summit Therapeutics in Q1 2025 and held it in 1 quarter.
SIH Partners's Summit Therapeutics position peaked at $897K in Q1 2025.
238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on SIH Partners's 13F filing for Q2 2025, filed 14 Aug 2025.